Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Outlook Therapeutics Inc.

    NASDAQ: OTLK · Real-Time Price · USD
    1.77
    -0.05 (-2.75%)
    At close: Jun 16, 2025, 3:59 PM
    1.75
    -1.38%
    After-hours: Jun 16, 2025, 07:19 PM EDT

    Outlook Therapeutics Statistics

    Share Statistics

    Outlook Therapeutics has 42.85M shares outstanding. The number of shares has increased by 39.37% in one year.

    Shares Outstanding

    n/a
    		 42.85M

    Shares Change (YoY)

    n/a
    		 39.37%

    Shares Change (QoQ)

    n/a
    		 30.98%

    Owned by Institutions (%)

    n/a
    		 17.72%

    Shares Floating

    n/a
    		 21.22M

    Failed to Deliver (FTD) Shares

    n/a
    		 15,993

    FTD / Avg. Volume

    n/a
    		 2.89%

    Short Selling Information

    The latest short interest is 3.22M, so 7.51% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.22M

    Short % of Shares Out

    n/a
    		 7.51%

    Short % of Float

    n/a
    		 9.2%

    Short Ratio (days to cover)

    n/a
    		 3.74

    Valuation Ratios

    The PE ratio is -1.31 and the forward PE ratio is -2.15. Outlook Therapeutics's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -1.31

    Forward PE

    n/a
    		 -2.15

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 -1.36

    P/FCF Ratio

    n/a
    		 -1.44

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Outlook Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.64, with a Debt / Equity ratio of -0.41.

    Current Ratio

    n/a
    		 0.64

    Quick Ratio

    n/a
    		 0.64

    Debt / Equity

    n/a
    		 -0.41

    Debt / EBITDA

    n/a
    		 -0.42

    Debt / FCF

    n/a
    		 -0.43

    Interest Coverage

    n/a
    		 -22.71

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-3,276,826.09

    Employee Count

    n/a
    		 23

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 2.8K

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -76.59% in the last 52 weeks. The beta is 0.31, so Outlook Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.31

    52-Week Price Change

    n/a
    		 -76.59%

    50-Day Moving Average

    n/a
    		 1.6

    200-Day Moving Average

    n/a
    		 3.02

    Relative Strength Index (RSI)

    n/a
    		 51.9

    Average Volume (20 Days)

    n/a
    		 552,817

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -71.7M

    Net Income

    n/a
    		 -75.37M

    EBITDA

    n/a
    		 -71.59M

    EBIT

    n/a
    		 -72.21M

    Earnings Per Share (EPS)

    n/a
    		 -9.84
    Full Income Statement

    Balance Sheet

    The company has 14.93M in cash and 29.74M in debt, giving a net cash position of -14.81M.

    Cash & Cash Equivalents

    n/a
    		 14.93M

    Total Debt

    n/a
    		 29.74M

    Net Cash

    n/a
    		 -14.81M

    Retained Earnings

    n/a
    		 -543.28M

    Total Assets

    n/a
    		 19,075.1B

    Working Capital

    n/a
    		 -7,015.1B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -68.79M and capital expenditures 0, giving a free cash flow of -68.79M.

    Operating Cash Flow

    n/a
    		 -68.79M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -68.79M

    FCF Per Share

    n/a
    		 -3.71
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    OTLK does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for OTLK is $9, which is 408.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $9

    Price Target Difference

    n/a
    		 408.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 14, 2024. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Mar 14, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -44.59

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist